[Analysis of prognostic factors of epithelial ovarian carcinoma].
OBJECTIVE
To assess prognostic factors impacted on overall survival in patients with epithelial ovarian carcinoma.


METHODS
Totally 170 patients with stages I-IV epithelial ovarian carcinoma admitted in Shanxi Provincial Cancer Hospital from Jan 2002 to Dec 2005 were analyzed by retrospective analysis.


RESULTS
The results showed that the prognostic factors of epithelial ovarian carcinomas were related to age, stage, histological type, pathological differential grade, the size of residues lesions and the number of course of chemotherapy (P < 0.01). The univariate analysis showed that family history was not related to the survival of epithelial ovarian carcinoma (P > 0.05). Compared with stage IV, the risk of mortality was 0.005 for stage I (95%CI, 0.001-0.024), 0.106 for stage II (95%CI, 0.038-0.297) and 0.361 (95%CI, 0.18-0.718) for stage III (P < 0.01). The risk of mortality was 0.307 (95%CI, 0.176-0.536) for the patients with residual diameter > 2 cm, in comparison with the residual < or = 2 cm (P < 0.01). The risk of mortality in patients received < 6 courses of chemotherapy was 8.191 times higher than that in patients received > or = 6 courses of chemotherapy (95%CI, 4.666 - 14.379; P < 0.01).


CONCLUSIONS
The major independent prognostic variables for epithelial ovarian carcinoma are stage, the size of residual tumor lesions and the number of courses of chemotherapy. Therefore, the earlier diagnosis, the earlier surgery, sufficient cycles and timely assistant chemotherapy are the key point to improve the survival rates of epithelial ovarian carcinoma.
Shao
Shu-li
SL
Department of Gynecology, Shanxi Provincial Cancer Hospital, Taiyuan 030013, China.
Liu
Xiao-su
XS
D018262:Adenocarcinoma, Clear Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy; D000328:Adult; D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D018284:Cystadenocarcinoma, Serous / Q000401:mortality / Q000473:pathology / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000401:mortality* / Q000473:pathology* / Q000601:surgery / Q000628:therapy; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000601:surgery / Q000628:therapy; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D055815:Young Adult
D003520:Cyclophosphamide; D017239:Paclitaxel